Lexaria Bioscience Corp Warrant 2020-12.01.26 on Lexaria Bioscience LEXXW 深 沪
等待开盘 09-10 09:30:00 美东时间
0.10
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.10
- 总市值 51.04万
- 52周最高 1.31
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.0685
- 委 比 -81.79%
- 总股本 510.43万
- 历史最高 5.19
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.05
- 每 手 1
- 风险率 0.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexaria Bioscience's Contract Research Organization Completes Last Patent Last Visit Study Milestone In Lexaria's Phase 1b Glucagon-Like Peptide-1 Study In Australia, GLP-1-H24-4
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization ("CRO") has completed the
08-14 21:23
Lexaria Bioscience Targets GLP-1 Market with DehydraTECH Innovation
Lexaria Bioscience ( ($LEXX) ) has shared an update. Lexaria Bioscience is posi...
08-06 22:42
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07312025_LEXX_Vandermosten.pdf
07-31 22:58
Lexaria’s DehydraTECH Technology Poised to Transform GLP-1 Industry
Lexaria Bioscience ( ($LEXX) ) just unveiled an announcement. Lexaria Bioscienc...
07-23 23:09
Lexaria's DehydraTECH Targets Side Effects In GLP-1 Market, Offers Relief For Semaglutide, Tirzepatide, And Liraglutide Users
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention and further
07-23 21:29
Lexaria Bioscience Prpvides Strategic Update Of Glucagon-Like Peptide-1
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention and further
07-23 21:28
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers DIH Holding US (NASDAQ:DHAI) shares rose 35.1% to $0.34 during Friday'...
07-19 05:06
Lexaria Bioscience Q3 EPS $(0.21) Misses $(0.16) Estimate, Sales $174.000K Beat $91.333K Estimate
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.16) by 33.76 percent. This is a 61.54 percent decrease over losses of $(0.13) per share
07-15 06:32
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5
HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $7 to $5.
07-01 19:40
Lexaria Bioscience Receives Two New Patents For Treatment Of Epilepsy And For Sublingual Delivery Of Nicotine
New patents received for the treatment of epilepsy and for the sublingual delivery of nicotineKELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or
06-23 21:18
